| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | IL-1 receptor-associated kinase 4; Interleukin 1 receptor associated kinase 4 mutant form 1; IPD1; IRAK4; LOC 51135; NY REN 64; REN64 |
| Entrez GeneID | 51135 |
| WB Predicted band size | Calculated MW: 52 kDa; Observed MW: 52 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human IRAK4 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇与IRAK4抗体相关的模拟参考文献示例(注：内容为虚构，仅作格式参考)：
---
1. **文献名称**: *"Development of a High-Affinity IRAK4 Antibody for Inflammatory Disease Research"*
**作者**: Smith A, et al.
**摘要**: 本研究报道了一种新型IRAK4单克隆抗体的开发，该抗体通过噬菌体展示技术筛选，具有高特异性和亲和力。实验验证了其在Western blot和免疫荧光中对IRAK4蛋白的检测能力，并证明其可阻断TLR/IL-1R信号通路，为炎症性疾病机制研究提供了工具。
---
2. **文献名称**: *"IRAK4 Inhibition by Neutralizing Antibodies Attenuates Autoimmune Arthritis in Murine Models"*
**作者**: Chen L, et al.
**摘要**: 通过制备靶向IRAK4激酶结构域的中和抗体，研究者证明了其在胶原诱导关节炎小鼠模型中显著降低促炎因子(如TNF-α、IL-6)水平，并缓解关节损伤，提示IRAK4抗体在自身免疫疾病治疗中的潜力。
---
3. **文献名称**: *"Comparative Analysis of Commercial IRAK4 Antibodies in Cancer Biomarker Detection"*
**作者**: Gupta R, et al.
**摘要**: 系统性评估了5种市售IRAK4抗体在肿瘤组织样本中的性能，发现部分抗体存在非特异性结合问题。研究推荐使用克隆号X的抗体，其在乳腺癌和淋巴瘤患者样本中表现出高敏感性和重复性，可用于癌症预后标志物研究。
---
(注：以上文献信息为模拟生成，实际引用请通过PubMed或Google Scholar等平台检索真实文献。)
**Background of IRAK4 Antibodies**
Interleukin-1 receptor-associated kinase 4 (IRAK4) is a critical serine/threonine kinase in the innate immune system, primarily involved in Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling pathways. Upon receptor activation, IRAK4 is recruited to the receptor complex, where it mediates downstream signaling through phosphorylation of substrates like IRAK1 and IRAK2. This triggers activation of NF-κB and MAPK pathways, leading to pro-inflammatory cytokine production and immune responses.
IRAK4 antibodies are essential tools for studying its expression, localization, and function in immune regulation. Dysregulation of IRAK4 is linked to autoimmune diseases, chronic inflammation, and cancers, making it a therapeutic target. For instance, IRAK4 inhibitors are explored for treating conditions like rheumatoid arthritis and lupus. Antibodies against IRAK4 enable detection in Western blot, immunohistochemistry, and flow cytometry, aiding mechanistic studies.
Additionally, inherited IRAK4 deficiencies in humans result in susceptibility to bacterial infections, highlighting its role in host defense. Research using IRAK4 antibodies has clarified its structural domains (N-terminal death domain, kinase domain) and interaction networks. Monoclonal and polyclonal antibodies are developed to target specific epitopes, facilitating both basic research and drug development. Overall, IRAK4 antibodies are pivotal in dissecting immune signaling and advancing targeted therapies.
×
